How does once-weekly dosing work?

A fatty-acid side chain lets it bind reversibly to albumin, slowing clearance so one weekly injection sustains growth hormone activity.

Is it as effective as daily growth hormone?

In trials it was non-inferior to daily somatropin for height velocity in children and comparable for body composition in adults.

Can somapacitan be used for anti-aging or muscle building?

No. It is only proven and approved for growth hormone deficiency; anti-aging or performance use of growth hormone is unproven and can be dangerous.

What monitoring does it require?

Endocrinologists track IGF-1 and watch for glucose intolerance, intracranial hypertension, hip and spine issues in children, and injection-site reactions.

EMA-approvedaka Sogroya

Somapacitan — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Somapacitan (also known as Sogroya) is a peptide catalogued under Hormones & Metabolic (Long-acting GH analog). It is described as: GH receptor. Documented context: GHD adults/children. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Somapacitan?

Somapacitan (brand name Sogroya) is a long-acting growth hormone derivative engineered with an albumin-binding fatty-acid side chain that reversibly binds circulating albumin to prolong its action, enabling once-weekly subcutaneous dosing.

It is an approved prescription medicine for adults with growth hormone deficiency (FDA 2020) and for children with GHD (FDA 2023; also approved in the EU).

Evidence is human and robust across the REAL clinical program, including phase 3 randomized trials in adults (REAL 1) and children (REAL 4).

How does Somapacitan work?

Somapacitan activates the growth hormone receptor to raise IGF-1 and promote linear growth (children) and favorable body composition (adults).

Reversible albumin binding slows renal and receptor-mediated clearance, sustaining GH exposure across a weekly dosing interval.

What does the research say about Somapacitan?

In treatment-naive children with GHD, once-weekly somapacitan produced annualized height velocity non-inferior to daily somatropin at 52 weeks (REAL 4). ^[2]
Growth efficacy and safety were maintained through two years of REAL 4, including in children switched from daily GH. ^[3]
In adults with GHD, once-weekly somapacitan improved body composition (reduced truncal fat) versus placebo and comparably to daily GH in a phase 3 trial. ^[1]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial — Johannsson G et al., Journal of Clinical Endocrinology and Metabolism 2020. (Phase 3 randomized controlled trial (REAL 1))
[2] Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial — Miller BS et al., Journal of Clinical Endocrinology and Metabolism 2022. (Phase 3 randomized controlled trial (REAL 4))
[3] Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH — Miller BS et al., Journal of Clinical Endocrinology and Metabolism 2023. (Phase 3 extension)
[4] Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial — Savendahl L et al., Journal of Clinical Endocrinology and Metabolism 2020. (Phase 2 randomized controlled trial (REAL 3))
[5] Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial — Johannsson G et al., European Journal of Endocrinology 2018. (Phase 3 randomized controlled trial)
[6] Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency — Takahashi Y et al., Pituitary 2023. (Pooled analysis of randomized trial data)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: somapacitan is administered as a once-weekly subcutaneous injection, with the starting dose and titration individualized by an endocrinologist using clinical response and IGF-1 levels.

This is educational background, not dosing advice; prescribing and adjustment must be done by a qualified clinician.

Side effects & safety profile

Safety mirrors the growth-hormone class: injection-site reactions occur, and monitoring covers glucose intolerance/diabetes risk, intracranial hypertension, slipped capital femoral epiphysis, and scoliosis progression in growing children.

It is contraindicated in acute critical illness and active malignancy, and should be used only under endocrinology supervision with IGF-1 monitoring.

Somapacitan is an approved GHD therapy, not an anti-aging or athletic-performance product; off-label use for those purposes is unsupported and risky.

Stacking & combinations

There is no evidence-based rationale for combining somapacitan with other growth hormone analogues, anabolic steroids, or unapproved peptides, and doing so may amplify metabolic and endocrine risks.

Finding Somapacitan vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved for growth hormone deficiency in both adults and children as a once-weekly injection; it is a prescription endocrine medicine.

References

[1] Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial — Johannsson G et al., Journal of Clinical Endocrinology and Metabolism 2020. PMID: 32022863. View sourceStudy: Phase 3 randomized controlled trial (REAL 1)Weekly somapacitan reduced truncal fat versus placebo and was comparable to daily GH in adults with GHD.
[2] Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial — Miller BS et al., Journal of Clinical Endocrinology and Metabolism 2022. PMID: 36062966. View sourceStudy: Phase 3 randomized controlled trial (REAL 4)Once-weekly somapacitan gave 52-week height velocity non-inferior to daily somatropin in treatment-naive children with GHD.
[3] Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH — Miller BS et al., Journal of Clinical Endocrinology and Metabolism 2023. PMID: 37406251. View sourceStudy: Phase 3 extensionHeight velocity and safety were maintained through two years, including after switching from daily GH.
[4] Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial — Savendahl L et al., Journal of Clinical Endocrinology and Metabolism 2020. PMID: 31917835. View sourceStudy: Phase 2 randomized controlled trial (REAL 3)Weekly somapacitan produced growth and IGF-1 responses comparable to daily GH, supporting dose selection for phase 3.
[5] Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial — Johannsson G et al., European Journal of Endocrinology 2018. PMID: 29500310. View sourceStudy: Phase 3 randomized controlled trialWeekly somapacitan was well tolerated with treatment convenience advantages over daily GH in adults.
[6] Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency — Takahashi Y et al., Pituitary 2023. PMID: 36380045. View sourceStudy: Pooled analysis of randomized trial dataWeekly somapacitan did not adversely affect glucose metabolism in adults with GHD, though standard monitoring remains warranted.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.